The CellBrief

Cell therapy continues to transform how we treat disease, and every milestone brings us closer to making advanced therapies more accessible to patients worldwide. CellBri is proud to celebrate a major achievement from our partner Grit Biotechnology, the U.S. FDA IND approval of GT307, a next‑generation dual gene‑knockout TIL therapy engineered to push the boundaries of solid tumor treatment.

GT307 uses a high‑fidelity CRISPR/AaCas12bMax gene‑editing system to overcome key challenges found in traditional TIL therapies, including functional exhaustion and limited cell persistence. This advanced design enhances antitumor activity and supports improved T cell durability in the tumor microenvironment.

Notably, GT307 shows promise against difficult‑to‑treat “cold” tumors, representing an important step forward in expanding the reach of solid tumor immunotherapy.

Grit Biotechnology’s achievement reflects the strength of their innovation platforms, including ImmuT Finder® and KOReTIL®, which enable the development of next‑generation engineered T‑cell therapies.

At CellBri, we’re committed to empowering developers like Grit with scalable, flexible manufacturing technologies built for precision and regulatory readiness. Our Gentle Flex‑Pro (automated cell processing instrument) and P‑Pac (fill and finish) systems further strengthen this support by delivering adaptable, closed‑system automation that brings added reliability across key processing and fill‑finish stages. Their progress underscores what’s possible when strong science meets advanced engineering.

With GT307 now cleared to advance into clinical development, we’re excited to support Grit Biotechnology as they continue driving meaningful progress in TIL‑based therapies and personalized medicine. This milestone aligns with CellBri’s mission to help teams simplify, scale, and accelerate how life‑changing cell therapies are made.

Congratulations to the entire Grit Bio team on this remarkable achievement. We look forward to the breakthroughs ahead!